Nov 2 U.S. regulators on Friday said they had
approved expanded use of Johnson & Johnson's Xarelto
blood thinner, to treat blood clots in the legs and lungs and to
reduce the risk of such clots recurring after initial treatment.
The pill is already approved to reduce the risk of such leg
clots, called deep vein thrombosis, and lung clots, following
knee or hip replacement surgery. It is also already approved to
prevent strokes in patients with an irregular heartbeat called
"Xarelto is the first oral anti-clotting drug approved to
treat and reduce the recurrence of blood clots since the
approval of warfarin 60 years ago," the FDA said in a release.